{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.94","upperLimit":"1.00","value":"0.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from step 1 registration to death of any cause. OS is censored at the date last known alive for cases that are alive. The 3-year OS rate is defined as the probability of patients remaining alive at 3 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"R-CHOP: Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients are evaluated 3 weeks after the last course of therapy. Patients with progressive disease go off study.\n\nZevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.\n\nRadiotherapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy.","id":"OG000","title":"Treatment"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 3 years; then annually to 10 years from patient entry.","title":"3-year Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"probability"}